Magnetization Transfer Imaging in Premanifest and Manifest Huntington Disease: A 2-Year Follow-Up

References

1. 1.↵
   1. Dehmeshki J,
   2. Chard DT,
   3. Leary SM,
   4. et al

   . The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol 2003;250:67–74

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Filippi M,
   2. Rocca MA

   . Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics 2007;4:401–13

   PubMed
3. 3.↵
   1. McGowan JC

   . The physical basis of magnetization transfer imaging. Neurology 1999;53(5 suppl 3):S3–7

   PubMedWeb of Science
4. 4.↵
   1. Ridha BH,
   2. Tozer DJ,
   3. Symms MR,
   4. et al

   . Quantitative magnetization transfer imaging in Alzheimer disease. Radiology 2007;244:832–37

   CrossRefPubMed
5. 5.↵
   1. Eckert T,
   2. Sailer M,
   3. Kaufmann J,
   4. et al

   . Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004;21:229–35

   CrossRefPubMedWeb of Science
6. 6.↵
   1. van den Bogaard SJ,
   2. Dumas EM,
   3. Milles J,
   4. et al

   . Magnetization transfer imaging in premanifest and manifest Huntington disease. AJNR Am J Neuroradiol 2012;33:884–89

   Abstract/FREE Full Text
7. 7.↵
   1. Ginestroni A,
   2. Battaglini M,
   3. Diciotti S,
   4. et al

   . Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease. AJNR Am J Neuroradiol 2010;31:1807–12

   Abstract/FREE Full Text
8. 8.↵
   A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes: the Huntington's Disease Collaborative Research Group. Cell 1993;72:971–83

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Langbehn DR,
   2. Brinkman RR,
   3. Falush D,
   4. et al

   . A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267–77

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Tabrizi SJ,
    2. Langbehn DR,
    3. Leavitt BR,
    4. et al

    . Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791–801

    CrossRefPubMedWeb of Science
11. 11.↵
    1. van den Bogaard SJ,
    2. Dumas EM,
    3. Acharya TP,
    4. et al

    . Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol 2011;258:412–20

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Dumas EM,
    2. van den Bogaard SJ,
    3. Ruber ME,
    4. et al

    . Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum Brain Mapp 2012;33:203–12

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Rosas HD,
    2. Tuch DS,
    3. Hevelone ND,
    4. et al

    . Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 2006;21:1317–25

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Rosas HD,
    2. Hevelone ND,
    3. Zaleta AK,
    4. et al

    . Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005;65:745–47

    Abstract/FREE Full Text
15. 15.↵
    1. Henley SM,
    2. Frost C,
    3. Macmanus DG,
    4. et al

    . Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology 2006;67:694–96

    Abstract/FREE Full Text
16. 16.↵
    1. Mascalchi M,
    2. Lolli F,
    3. Della NR,
    4. et al

    . Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004;232:867–73

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Jurgens CK,
    2. Bos R,
    3. Luyendijk J,
    4. et al

    . Magnetization transfer imaging in ‘premanifest’ Huntington's disease. J Neurol 2010;257:426–32

    CrossRefPubMed
18. 18.↵
    1. van Waesberghe JH,
    2. Kamphorst W,
    3. De Groot CJ,
    4. et al

    . Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747–54

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Filippi M,
    2. Rocca MA,
    3. Comi G

    . The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. Lancet Neurol 2003;2:337–46

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Tabrizi SJ,
    2. Scahill RI,
    3. Durr A,
    4. et al

    . Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31–42

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Penney JB Jr.,
    2. Vonsattel JP,
    3. MacDonald ME,
    4. et al

    . CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689–92

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Zhang Y,
    2. Brady M,
    3. Smith S

    . Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001;20:45–57

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Patenaude B,
    2. Smith SM,
    3. Kennedy DN,
    4. et al

    . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907–22

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Woolrich MW,
    4. et al

    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208–19

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Smith SM,
    2. Zhang Y,
    3. Jenkinson M,
    4. et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Melzi L,
    2. Rocca MA,
    3. Marzoli SB,
    4. et al

    . A longitudinal conventional and magnetization transfer magnetic resonance imaging study of optic neuritis. Mult Scler 2007;13:265–68

    Abstract/FREE Full Text
27. 27.↵
    1. Mesaros S,
    2. Rocca M,
    3. Sormani M,
    4. et al

    . Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. Mult Scler 2010;16:325–31

    Abstract/FREE Full Text
28. 28.↵
    1. Filippi M,
    2. Inglese M,
    3. Rovaris M,
    4. et al

    . Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. Neurology 2000;55:940–46

    Abstract/FREE Full Text
29. 29.↵
    1. Emmer BJ,
    2. Steens SC,
    3. Steup-Beekman GM,
    4. et al

    . Detection of change in CNS involvement in neuropsychiatric SLE: a magnetization transfer study. J Magn Reson Imaging 2006;24:812–16

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Ge Y,
    2. Grossman RI,
    3. Babb JS,
    4. et al

    . Age-related total gray matter and white matter changes in normal adult brain. Part II. Quantitative magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol 2002;23:1334–41

    Abstract/FREE Full Text
31. 31.↵
    1. Tabrizi SJ,
    2. Reilmann R,
    3. Roos RA,
    4. et al

    . Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11:42–53

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Paulsen JS,
    2. Magnotta VA,
    3. Mikos AE,
    4. et al

    . Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006;59:57–63

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Zimbelman JL,
    2. Paulsen JS,
    3. Mikos A,
    4. et al

    . fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc 2007;13:758–69

    PubMedWeb of Science
34. 34.↵
    1. Paulsen JS,
    2. Zimbelman JL,
    3. Hinton SC,
    4. et al

    . fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol 2004;25:1715–21

    Abstract/FREE Full Text